The world of small-cap health care investing is one of huge booms and major busts. However, equities.com's Small-Cap Stars, our proprietary list of small-cap companies with characteristics we've found to be most predictive of future success, helps you find those companies with a strong foundation that are best positioned to capitalize on future success.
Here are today's top-performing health care Small-Cap Stars as of noon on the east coast:
Insys Therapeutics Inc (INSY)
Insys Therapeutics Inc gained 8.18% to $34.39 in morning trading today. Volume reached 436,029 by noon. The stock's average daily volume is 568,098 shares. Insys Therapeutics Inc has a 52-week high of $57.91 and a 52-week low of $12.53, its P/E ratio is 22.6, and its 50-day SMA and 200-day SMA are $27.80 and $32.89 respectively.
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. It develops and commercializes supportive care products that target the unmet needs of cancer patients, with an initial focus on cancer supportive care.
Fonar Corporation (FONR)
Fonar Corporation gained 7.63% to $12.27 in morning trading today. Volume reached 108,121 by noon. The stock's average daily volume is 67,351 shares. Fonar Corporation has a 52-week high of $27.95 and a 52-week low of $5.12, its P/E ratio is 6.2, and its 50-day SMA and 200-day SMA are $11.75 and $16.15 respectively.
Fonar Corp is engaged in the research, development, production and marketing of medical scanning equipment, which uses principles of Magnetic Resonance Imaging (MRI) for the detection and diagnosis of human diseases.
Inovio Pharmaceuticals Inc. (INO)
Inovio Pharmaceuticals Inc. gained 7.37% to $9.32 in morning trading today. Volume reached 1,090,980 by noon. The stock's average daily volume is 1,818,266 shares. Inovio Pharmaceuticals Inc. has a 52-week high of $15.80 and a 52-week low of $4.88, and its 50-day SMA and 200-day SMA are $10.10 and $10.23 respectively.
Inovio Pharmaceuticals, Inc. is a biomedical company, engaged in the development of next-generation vaccines to prevent or treat cancers and chronic infectious diseases.
Horizon Pharma Inc. (HZNP)
Horizon Pharma Inc. gained 6.62% to $9.99 in morning trading today. Volume reached 717,371 by noon. The stock's average daily volume is 2,490,459 shares. Horizon Pharma Inc. has a 52-week high of $18.30 and a 52-week low of $2.11, and its 50-day SMA and 200-day SMA are $13.61 and $11.19 respectively.
Horizon Pharma Inc is a specialty pharmaceutical company. It has developed and is commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammatory diseases.
Dyax Corp. (DYAX)
Dyax Corp. gained 6.39% to $9.91 in morning trading today. Volume reached 626,794 by noon. The stock's average daily volume is 989,873 shares. Dyax Corp. has a 52-week high of $10.99 and a 52-week low of $4.00, and its 50-day SMA and 200-day SMA are $8.90 and $8.36 respectively.
Dyax Corp is a biotechnology company, which is engaged in the discovery, development and commercialization of biopharmaceuticals for unmet medical needs.
Equities.com's Health Care Small-Cap Stars - Helping You Build a Healthier Portfolio
There's no crystal ball that will tell you what the outcome of this or that clinical trial is going to be. Even if there were, the one astonishingly wealthy person who owns it probably wouldn't share. But that doesn't mean that investing in the right small-cap health care companies can't pay dividends in the long term. While the future of a company's lead therapy may not be certain, most of its present fundamentals are. And while investing in the small-cap biotech market will always be hit-or-miss, investing in solidly built players should help boost that batting average.
Our Small-Cap Stars system uses a complex statistical regression to isolate those fundamental factors that previous success stories had in common and then identifies those small caps that are the most similar to that profile in the present.
For health care companies, we found that a high enterprise value, a strong value line beta, and a high rate of reinvestment were among the most indicative of a small-cap company's potential for success.
All data provided by QuoteMedia and was accurate as of 12:00 pm ET.